Expansion of circulating toll-like receptor 4-positive monocytes in patients with acute coronary syndrome

Circulation

Volumn 111, Issue 20, 2005, Pages 2654-2661

  Methe, Heiko ^a,b   Kim, Jong Oh ^a   Kofler, Sieglinde ^a   Weis, Michael ^a   Nabauer, Michael ^a   Koglin, Joerg ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cell surface; Coronary disease; Immune system; Monocytes; Receptors

Indexed keywords

HEAT SHOCK PROTEIN 60; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CELL ACTIVATION; CHINESE HAMSTER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OVARY CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; UPREGULATION;

ACUTE DISEASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; ANGINA PECTORIS; ANTIGENS, DIFFERENTIATION; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CELL PROLIFERATION; FEMALE; HEART DISEASES; HUMANS; LIGANDS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; MYELOID DIFFERENTIATION FACTOR 88; MYOCARDIAL INFARCTION; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; TOLL-LIKE RECEPTOR 4;

EID: 19644390754     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.498865     Document Type: Article

References (41)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91: 281-291.
3. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388;394-397.
4. Heine H, Lien E. Toll-like receptors and their function in innate and adaptive immunity, Int Arch Allergy Immunol. 2003;130:180-192.
5. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/ 10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085-2088.
6. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, Golenbock DT. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest. 2000; 105:497-504.
7. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol. 2001;167: 2887-2894.
8. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells, J Biol Chem. 2003;278:1561-1568.
9. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000;164:558-561.
10. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001;2:947-950.
11. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M. Toll-like receptor-4 is expressed by macrophages in mutine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001;104:3103-3108.
12. Edfeldt K, Swedenborg J, Hansson GK, Van ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105:1158-1161.
13. Hollestelle SC, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, Strijder CF, Van Middelaar BJ. Pasterkamp G, Quax PH, De Kleijn DP. Toll-like receptor 4 is involved in outward arterial remodeling. Circulation. 2004;109:393-398.
14. Liuzzo G, Angiolillo DJ, Buffon A, Rizzello V. Colizzi C, Ginnetti F, Biasucci LM, Maseri A. Enhanced response of blood monocytes to in vitro lipopolysaccharide challenge in patients with recurrent unstable angina. Circulation. 2001;103:2236-2241.
15. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol. 2004;22:361-403.
16. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-969.
17. Vink A, Schoneveld AH, van der Meer JJ, van Middelaar BJ, Sluijter JP, Smeets MB, Quax PH, Lim SK, Borst C, Pasterkamp G, de Kleijn DP. In vivo evidence for a role of toll-like receptor 4 in the development of intimai lesions, Circulation. 2002;106:1985-1990.
18. Zal B, Kaski JC, Arno G, Akiyu JP, Xu Q, Cole D, Whelan M, Russell N, Madrigal JA, Dodi IA, Baboonian C. Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes. Circulation. 2004;109:1230-1235.
19. Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, Lichtman AH. B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 2004;109:2009-2015.
20. Pasterkamp G, Schoneveld AH, van der Wal AC, Haudenschild CC, Clarijs RJ, Becker AE, Hillen B, Borst C. Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. J Am Coll Cardiol. 1998;32:655-662.
21. Wright SD, Burton C, Hernandez M, Hassing H, Montenegro J, Mundt S, Patel S, Card DJ, Hermanowski-Vosatka A, Bergstrom JD, Sparrow CP, Detmers PA, Chao YS. Infectious agents are not necessary for murine atherogenesis. J Exp Med. 2000;191:1437-1442.
22. Gao B, Tsan MF. Recombinant human heat shock protein 60 does not induce the release of tumor necrosis factor alpha from murine macrophages. J Biol Chem. 2003;278:22523-22529.
23. Gao B, Tsan MF. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. J Biol Chem. 2003;278:174-179.
24. Bausinger H, Lipsker D, Ziylan U, Manie S, Briand JP, Cazenave JP, Muller S, Haeuw JF, Ravanat C, de la Salle H, Hanau D. Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur J Immunol. 2002;32:3708-3713.
25. Medvedev AE, Kopydlowski KM, Vogel SN. Inhibition of lipopolysaccharide- induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression, J Immunol. 2000;164:5564-5574.
26. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M, Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol. 2001;167:1609-1616.
27. Bosisio D, Polentarutti N, Sironi M, Bernasconi S, Miyake K, Webb GR, Martin MU, Mantovani A, Muzio M. Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood. 2002;99:3427-3431.
28. Mosmann TR, Coffman RL. TH1 and TH2 cells; different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-173.
29. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H. Concentrations of interleukins, Interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol. 2003;91:133-136.
30. Zhou X, Nicoletti A, Elhage R, Hansson GK, Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000;102:2919-2922.
31. Tamai R, Sugawara S, Takeuchi O, Akira S, Takada H. Synergistic effects of lipopolysaccharide and interferon-gamma in inducing interleukin-8 production in human monocytic THP-1 cells is accompanied by up-regulation of CD 14, Toll-like receptor 4, MD-2 and MyD88 expression. J Endowxin Res. 2003;9:145-153.
32. Oshikawa K, Sugiyama Y. Gene expression of Toll-like receptors and associated molecules induced by inflammatory stimuli in the primary alveolar macrophage. Biochem Biophys Res Commun. 2003:305: 649-655.
33. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004;10:416-421.
34. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA, Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185-192.
35. Kiechl S, Wiedermann CJ, Willeit J. Toll-like receptor 4 and atherogenesis. Ann Med. 2003:35:164-171.
36. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004;101:10679-10684.
37. Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest. 2004;34:328-334.
38. Walle TK, Vartio T, Helve T, Virtanen I, Kurki P. Cellular fibronectin in rheumatoid synovium and synovial fluid: a possible factor contributing to lymphocytic infiltration. Scand J Immunol. 1990;31:535-540.
39. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 2000;60:7099-7105.
40. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF III. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001;276:10229-10233.
41. Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, Reitsma PH, Kastelein JJ, Jukema JW. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation. 2003;107:2416-2421.